Quest Diagnostics Inc Restructuring Costs and Asset Impairment Charges
Quest Diagnostics Inc (DGX) reported Restructuring Costs and Asset Impairment Charges of $11.00 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2025-10-21
- Quest Diagnostics Inc restructuring costs and asset impairment charges for the quarter ending 2025-09-30 was $11.00M, a 57.14% increase year-over-year.
- Quest Diagnostics Inc restructuring costs and asset impairment charges for the quarter ending 2025-06-30 was $25.00M, a 212.50% increase year-over-year.
- Quest Diagnostics Inc restructuring costs and asset impairment charges for the quarter ending 2024-09-30 was $7.00M, a 600.00% increase year-over-year.
- Quest Diagnostics Inc restructuring costs and asset impairment charges for the quarter ending 2024-06-30 was $8.00M, a 33.33% increase year-over-year.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month |
|---|---|---|---|
| 2025-09-30 | $11.00M 10-Q · filed 2025-10-21 | $36.00M derived: sum of 2 quarters · filed 2025-10-21 | $47.00M 10-Q · filed 2025-10-21 |
| 2025-06-30 | $25.00M 10-Q · filed 2025-07-23 | $36.00M 10-Q · filed 2025-07-23 | |
| 2024-09-30 | $7.00M 10-Q · filed 2025-10-21 | $15.00M derived: sum of 2 quarters · filed 2025-10-21 | $21.00M 10-Q · filed 2025-10-21 |
| 2024-06-30 | $8.00M 10-Q · filed 2025-07-23 | $14.00M 10-Q · filed 2025-07-23 | |
| 2023-09-30 | $1.00M 10-Q · filed 2024-10-23 | $7.00M derived: sum of 2 quarters · filed 2024-10-23 | $22.00M 10-Q · filed 2024-10-23 |
| 2023-06-30 | $6.00M 10-Q · filed 2024-07-24 | $21.00M 10-Q · filed 2024-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |